Our findings reveal a striking dependency in MM on both CARM1 targeting and CRBN-mediated IKZF3 protein degradation, as simultaneous blockade of both pathways leads to robust MM cell killing with substantially greater potency than CARM1 inhibition or IMiD treatment alone. This evidence concerns the gene CRBN and Miyoshi myopathy.